X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (266) 266
female (158) 158
animals (138) 138
male (133) 133
phthalazines - pharmacokinetics (126) 126
phthalazines - pharmacology (119) 119
phthalazines - administration & dosage (116) 116
phthalazines - therapeutic use (100) 100
oncology (98) 98
pharmacology & pharmacy (97) 97
adult (83) 83
middle aged (80) 80
aged (68) 68
phthalazines - adverse effects (68) 68
cancer (63) 63
mice (63) 63
olaparib (56) 56
phthalazines - chemistry (52) 52
piperazines - pharmacology (50) 50
poly polymerase (47) 47
rats (46) 46
piperazines - administration & dosage (44) 44
treatment outcome (43) 43
pharmacokinetics (41) 41
piperazines - therapeutic use (41) 41
tumors (40) 40
antineoplastic agents - therapeutic use (39) 39
neoplasms - drug therapy (38) 38
administration, oral (37) 37
cell line, tumor (37) 37
piperazines - pharmacokinetics (37) 37
dose-response relationship, drug (36) 36
analysis (34) 34
antineoplastic agents - pharmacology (34) 34
breast cancer (33) 33
chemotherapy (33) 33
poly polymerase inhibitors (33) 33
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
azelastine (30) 30
chemistry, medicinal (30) 30
ovarian cancer (30) 30
medicine & public health (29) 29
ovarian neoplasms - drug therapy (29) 29
piperazines - adverse effects (29) 29
poly polymerase inhibitors - pharmacology (28) 28
pyridines - administration & dosage (28) 28
angiogenesis (26) 26
inhibitors (26) 26
mutation (26) 26
pharmacology (26) 26
care and treatment (25) 25
mice, nude (25) 25
research (25) 25
administration, intranasal (24) 24
antineoplastic agents - pharmacokinetics (24) 24
dna damage (24) 24
double-blind (24) 24
pharmacology/toxicology (24) 24
therapy (24) 24
antineoplastic agents - adverse effects (23) 23
breast neoplasms - drug therapy (23) 23
cell proliferation - drug effects (23) 23
inhibition (23) 23
inhibitor (23) 23
maintenance therapy (23) 23
maximum tolerated dose (23) 23
parp inhibitor (23) 23
rhinitis, allergic, seasonal - drug therapy (23) 23
structure-activity relationship (23) 23
xenograft model antitumor assays (23) 23
aged, 80 and over (22) 22
clinical trials (22) 22
combination (22) 22
dna repair (22) 22
phthalazines - blood (22) 22
safety (22) 22
apoptosis - drug effects (21) 21
biological availability (21) 21
phthalazines - metabolism (21) 21
antineoplastic agents - administration & dosage (20) 20
double-blind method (20) 20
drug therapy (20) 20
endothelial growth-factor (20) 20
monosaccharides (20) 20
ovarian-cancer (20) 20
phthalazines - chemical synthesis (20) 20
poly polymerases - metabolism (20) 20
pyridines - pharmacology (20) 20
sugars (20) 20
cancer therapies (19) 19
cells (19) 19
deoxyribonucleic acid--dna (19) 19
expression (19) 19
open-label (19) 19
patients (19) 19
pyridines - pharmacokinetics (19) 19
adolescent (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (18) 18
dna-repair (18) 18
enzyme inhibitors - pharmacology (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Clinical Pharmacology, ISSN 0091-2700, 2019, Volume 59, Issue 12, pp. 1678 - 1689
...‐state pharmacokinetics (PK) of hydralazine during pregnancy and evaluate the effects of NAT2 genotype on hydralazine and MTP PK during pregnancy, 12 pregnant subjects received oral hydralazine (5‐25 mg every 6 hours) in mid‐ (n = 5... 
pharmacokinetics | 3‐methyl‐1,2,4‐triazolo[3,4‐a]phthalazine | hydralazine | NAT2 | hypertension | pregnancy | Pregnancy | Genotype & phenotype | Parameter estimation | Metabolites | Pharmacology | Acetyltransferase | Acetylation | Pharmacokinetics | Gestational age | Antihypertensive agents | Genotypes | Weight | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2017, Volume 35, Issue 19, pp. 2193 - 2202
...). Response rate and pharmacokinetic analysis were secondary end points. Results Between June 2015 and May 2016, 26 women were enrolled... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Clinical cancer research, ISSN 1557-3265, 2017, Volume 23, Issue 6, pp. 1397 - 1406
.... We evaluated sequence-specific pharmacokinetic and pharmacodynamic effects, safety, and activity of the combination... 
EXCISION-REPAIR | BREAST-CANCER | ONCOLOGY | PLATINUM | SENSITIVE OVARIAN-CANCER | DNA-REPAIR | COMBINATION | MAINTENANCE THERAPY | DAMAGE | CHEMOTHERAPY | PARP INHIBITOR | Piperazines - administration & dosage | Drug-Related Side Effects and Adverse Reactions - blood | Phthalazines - pharmacokinetics | Uterine Neoplasms - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Carboplatin - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions - pathology | Carboplatin - adverse effects | Neoplasm Recurrence, Local - pathology | Adult | Female | Piperazines - pharmacokinetics | DNA Adducts - blood | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Leukocytes, Mononuclear - drug effects | Phthalazines - administration & dosage | Drug Administration Schedule | Carboplatin - administration & dosage | Ovarian Neoplasms - blood | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Leukocytes, Mononuclear - pathology | Maximum Tolerated Dose | Breast Neoplasms - pathology | Uterine Neoplasms - drug therapy | Breast Neoplasms - blood | Aged | Phthalazines - adverse effects | Uterine Neoplasms - blood | Tablets | Toxicity | Cytotoxicity | Comet assay | Metastases | Platinum | Safety engineering | Deoxyribonucleic acid--DNA | Adducts | Neutropenia | Thrombocytopenia | Bioassay | Bioassays | Poly(ADP-ribose) polymerase | Pharmacology | Breast cancer | Bioavailability | Patients | Carriers | Damage detection | Experimental design | Carboplatin | DNA adducts | Intracellular | Uterine cancer | Pharmacokinetics | Cancer | Index Medicus
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 11/2014, Volume 78, Issue 5, pp. 1005 - 1013
Aims Vatalanib is an oral anti‐angiogenesis agent that inhibits vascular endothelial growth factor receptor tyrosine kinases, which in patients showed auto induction of metabolism and variability in pharmacokinetic (PK) disposition... 
population pharmacokinetic model | autoinduction | time‐dependent clearance | vatalanib | Population pharmacokinetic model | Autoinduction | Time-dependent clearance | Vatalanib | INCREASED ANGIOGENESIS | MODEL | INDUCTION | CANCER | LIVER METASTASES | time-dependent clearance | TIME-DEPENDENT PHARMACOKINETICS | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | PHASE-I | ENDOTHELIAL GROWTH-FACTOR | Prospective Studies | Area Under Curve | Phthalazines - pharmacokinetics | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Metabolic Clearance Rate | Young Adult | Angiogenesis Inhibitors - administration & dosage | Pyridines - adverse effects | Time Factors | Computer Simulation | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Angiogenesis Inhibitors - adverse effects | Myelodysplastic Syndromes - drug therapy | Pyridines - therapeutic use | Data Interpretation, Statistical | Myelodysplastic Syndromes - metabolism | Phthalazines - administration & dosage | Pyridines - administration & dosage | Angiogenesis Inhibitors - pharmacokinetics | Phthalazines - therapeutic use | Models, Biological | Aged | Phthalazines - adverse effects | Physiological aspects | Plants | Angiogenesis inhibitors | Endothelial growth factors | Phosphotransferases | Analysis | Index Medicus | Pharmacokinetics
Journal Article
Clinical cancer research, ISSN 1557-3265, 2009, Volume 15, Issue 5, pp. 1612 - 1622
Purpose: Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001 (everolimus) and the vascular... 
pharmacokinetics | DCE-MRI | RAD001 | angiogenesis | PTK/ZK | MAMMALIAN TARGET | RAPAMYCIN | IN-VITRO | GROWTH-FACTOR-RECEPTOR | ANGIOGENESIS | ONCOLOGY | MAGNETIC-RESONANCE | CELL-PROLIFERATION | MODEL | TUMOR VASCULATURE | CANCER | Protein Kinases - metabolism | Phthalazines - pharmacokinetics | Humans | Protein Kinases - chemistry | Pyridines - pharmacokinetics | Transplantation, Heterologous | Vascular Endothelial Growth Factor A - metabolism | Immunoenzyme Techniques | Tissue Distribution | Rats, Inbred BN | Receptors, Vascular Endothelial Growth Factor - metabolism | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Receptor, TIE-2 - metabolism | Everolimus | Rats, Inbred WF | Protein Kinase Inhibitors - pharmacokinetics | Sirolimus - analogs & derivatives | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Rats | Angiogenesis Inhibitors - pharmacokinetics | Sirolimus - pharmacokinetics | Sirolimus - pharmacology | Cell Movement - drug effects | Magnetic Resonance Imaging | Phthalazines - pharmacology | Animals | Neovascularization, Pathologic - drug therapy | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | TOR Serine-Threonine Kinases | Neoplasms, Experimental - metabolism | Neoplasms, Experimental - drug therapy | Neoplasms, Experimental - blood supply
Journal Article
Investigational new drugs, ISSN 1573-0646, 2011, Volume 30, Issue 4, pp. 1493 - 1500
Background The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered... 
Medicine & Public Health | Targeted agents | PARP inhibitors | Oncology | Topotecan | Olaparib | Maximum tolerated dose | Pharmacology/Toxicology | DNA repair | SENSITIVITY | INDUCTION | CANCER | MAMMARY-TUMORS | ONCOLOGY | RESISTANCE | PHARMACOLOGY & PHARMACY | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Demography | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Topotecan - adverse effects | Treatment Outcome | Piperazines - therapeutic use | Neoplasms - diagnostic imaging | Topotecan - therapeutic use | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | Maximum Tolerated Dose | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - pharmacokinetics | Topotecan - administration & dosage | Aged | Phthalazines - adverse effects | Cohort Studies | Studies | Clinical trials | Inhibitor drugs | Drug therapy | Patients | Tumors | Index Medicus
Journal Article
Journal Article
Annals of oncology, ISSN 0923-7534, 2017, Volume 28, Issue 3, pp. 512 - 518
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2016, Volume 38, Issue 10, pp. 2286 - 2299
Journal Article
Journal Article